Natera Inc (NASDAQ:NTRA) CFO Sells $1,274,666.00 in Stock

Natera Inc (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 43,954 shares of the stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $29.00, for a total value of $1,274,666.00. Following the transaction, the chief financial officer now owns 26,690 shares of the company’s stock, valued at approximately $774,010. The transaction was disclosed in a filing with the SEC, which is available at this link.

Michael Burkes Brophy also recently made the following trade(s):

  • On Monday, June 24th, Michael Burkes Brophy sold 275 shares of Natera stock. The stock was sold at an average price of $25.19, for a total value of $6,927.25.
  • On Monday, June 10th, Michael Burkes Brophy sold 747 shares of Natera stock. The stock was sold at an average price of $24.79, for a total value of $18,518.13.

Shares of NASDAQ NTRA traded down $3.07 during mid-day trading on Monday, hitting $29.31. The company had a trading volume of 1,387,921 shares, compared to its average volume of 687,935. The company has a market cap of $2.22 billion, a P/E ratio of -13.63 and a beta of 1.51. The company has a 50-day moving average price of $27.04. The company has a quick ratio of 1.73, a current ratio of 1.85 and a debt-to-equity ratio of 20.88. Natera Inc has a one year low of $11.08 and a one year high of $33.25.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Wednesday, August 7th. The medical research company reported ($0.48) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.57) by $0.09. The company had revenue of $74.36 million during the quarter, compared to analysts’ expectations of $66.77 million. Natera had a negative return on equity of 409.49% and a negative net margin of 46.78%. Natera’s revenue for the quarter was up 17.9% compared to the same quarter last year. During the same quarter last year, the company earned ($0.62) EPS. On average, sell-side analysts forecast that Natera Inc will post -2.1 earnings per share for the current year.

A number of research firms have issued reports on NTRA. Piper Jaffray Companies increased their target price on Natera from $28.00 to $32.00 and gave the stock an “overweight” rating in a report on Thursday. Canaccord Genuity increased their target price on Natera from $32.00 to $36.00 and gave the stock a “buy” rating in a report on Thursday. Craig Hallum increased their target price on Natera from $29.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday. Zacks Investment Research upgraded Natera from a “sell” rating to a “hold” rating in a report on Friday. Finally, BidaskClub upgraded Natera from a “hold” rating to a “buy” rating in a report on Friday. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $32.29.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Legal & General Group Plc grew its holdings in shares of Natera by 14.5% in the 4th quarter. Legal & General Group Plc now owns 5,826 shares of the medical research company’s stock valued at $81,000 after acquiring an additional 736 shares in the last quarter. JGP Global Gestao de Recursos Ltda. grew its holdings in shares of Natera by 10.5% in the 1st quarter. JGP Global Gestao de Recursos Ltda. now owns 13,518 shares of the medical research company’s stock valued at $279,000 after acquiring an additional 1,280 shares in the last quarter. Focused Wealth Management Inc bought a new position in shares of Natera in the 2nd quarter valued at about $83,000. State Board of Administration of Florida Retirement System grew its holdings in shares of Natera by 37.2% in the 2nd quarter. State Board of Administration of Florida Retirement System now owns 15,755 shares of the medical research company’s stock valued at $435,000 after acquiring an additional 4,270 shares in the last quarter. Finally, Bank of Montreal Can bought a new position in shares of Natera in the 2nd quarter valued at about $129,000. Institutional investors own 80.12% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Featured Story: Why is the price-sales ratio important?

Insider Buying and Selling by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit